Catalyst Pharmaceuticals, Inc. (CPRX)
USD 21.4
(-1.88%)
USD 21.4
(-1.88%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 86.81 Million USD | -14.75% |
| 2022 | 101.83 Million USD | 94.4% |
| 2021 | 52.38 Million USD | 26.83% |
| 2020 | 41.3 Million USD | 29.79% |
| 2019 | 31.82 Million USD | 190.16% |
| 2018 | -35.29 Million USD | -88.95% |
| 2017 | -18.67 Million USD | 3.11% |
| 2016 | -19.28 Million USD | 5.48% |
| 2015 | -20.39 Million USD | -39.8% |
| 2014 | -14.59 Million USD | -41.5% |
| 2013 | -10.31 Million USD | -97.5% |
| 2012 | -5.22 Million USD | 14.16% |
| 2011 | -6.08 Million USD | -51.14% |
| 2010 | -4.02 Million USD | 44.69% |
| 2009 | -7.27 Million USD | 33.22% |
| 2008 | -10.89 Million USD | -116.7% |
| 2007 | -5.02 Million USD | -73.21% |
| 2006 | -2.9 Million USD | -59.28% |
| 2005 | -1.82 Million USD | -235.6% |
| 2004 | -542.95 Thousand USD | -26.68% |
| 2003 | -428.61 Thousand USD | -67.46% |
| 2002 | -255.94 Thousand USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | 54.24 Million USD | 99.98% |
| 2024 Q1 | 27.12 Million USD | -34.94% |
| 2023 Q4 | 41.69 Million USD | 212.11% |
| 2023 FY | 86.81 Million USD | -14.75% |
| 2023 Q2 | 46.69 Million USD | 31.14% |
| 2023 Q3 | -37.18 Million USD | -179.63% |
| 2023 Q1 | 35.6 Million USD | 15.61% |
| 2022 Q3 | 25.1 Million USD | -12.14% |
| 2022 Q4 | 30.8 Million USD | 22.7% |
| 2022 Q1 | 17.36 Million USD | 36.29% |
| 2022 Q2 | 28.56 Million USD | 64.51% |
| 2022 FY | 101.83 Million USD | 94.4% |
| 2021 Q2 | 15.83 Million USD | 61.6% |
| 2021 Q1 | 9.8 Million USD | 13.73% |
| 2021 Q4 | 12.74 Million USD | -9.01% |
| 2021 FY | 52.38 Million USD | 26.83% |
| 2021 Q3 | 14 Million USD | -11.58% |
| 2020 Q3 | 11.7 Million USD | 13.83% |
| 2020 Q1 | 10.69 Million USD | 33.64% |
| 2020 FY | 41.3 Million USD | 29.79% |
| 2020 Q2 | 10.28 Million USD | -3.91% |
| 2020 Q4 | 8.61 Million USD | -26.37% |
| 2019 Q3 | 13.84 Million USD | 26.33% |
| 2019 FY | 31.82 Million USD | 190.16% |
| 2019 Q1 | -987.76 Thousand USD | 93.35% |
| 2019 Q2 | 10.95 Million USD | 1209.49% |
| 2019 Q4 | 8 Million USD | -42.17% |
| 2018 Q2 | -6.33 Million USD | -6.78% |
| 2018 Q1 | -5.93 Million USD | -7.65% |
| 2018 FY | -35.29 Million USD | -88.95% |
| 2018 Q4 | -14.84 Million USD | -81.4% |
| 2018 Q3 | -8.18 Million USD | -29.15% |
| 2017 Q4 | -5.51 Million USD | -27.98% |
| 2017 FY | -18.67 Million USD | 3.11% |
| 2017 Q2 | -4.18 Million USD | 10.65% |
| 2017 Q1 | -4.67 Million USD | -8.48% |
| 2017 Q3 | -4.3 Million USD | -3.0% |
| 2016 Q4 | -4.31 Million USD | -10.22% |
| 2016 Q1 | -6.23 Million USD | -0.74% |
| 2016 Q3 | -3.91 Million USD | 18.7% |
| 2016 FY | -19.28 Million USD | 5.48% |
| 2016 Q2 | -4.81 Million USD | 22.81% |
| 2015 Q4 | -6.19 Million USD | -23.4% |
| 2015 Q1 | -4.29 Million USD | -7.73% |
| 2015 Q2 | -4.89 Million USD | -14.11% |
| 2015 FY | -20.39 Million USD | -39.8% |
| 2015 Q3 | -5.01 Million USD | -2.45% |
| 2014 Q2 | -2.99 Million USD | 14.77% |
| 2014 FY | -14.59 Million USD | -41.5% |
| 2014 Q4 | -3.98 Million USD | 3.05% |
| 2014 Q3 | -4.1 Million USD | -37.42% |
| 2014 Q1 | -3.5 Million USD | -29.61% |
| 2013 FY | -10.31 Million USD | -97.5% |
| 2013 Q1 | -1.7 Million USD | -13.29% |
| 2013 Q2 | -2.65 Million USD | -55.59% |
| 2013 Q3 | -3.24 Million USD | -22.32% |
| 2013 Q4 | -2.7 Million USD | 16.6% |
| 2012 Q4 | -1.5 Million USD | -17.27% |
| 2012 Q1 | -1.36 Million USD | 32.92% |
| 2012 Q3 | -1.28 Million USD | -20.27% |
| 2012 FY | -5.22 Million USD | 14.16% |
| 2012 Q2 | -1.06 Million USD | 21.79% |
| 2011 Q4 | -2.03 Million USD | -79.88% |
| 2011 FY | -6.08 Million USD | -51.14% |
| 2011 Q2 | -1.39 Million USD | 8.02% |
| 2011 Q1 | -1.51 Million USD | -107.5% |
| 2011 Q3 | -1.13 Million USD | 19.07% |
| 2010 FY | -4.02 Million USD | 44.69% |
| 2010 Q3 | -908.46 Thousand USD | 31.85% |
| 2010 Q2 | -1.33 Million USD | -26.92% |
| 2010 Q1 | -1.05 Million USD | 10.2% |
| 2010 Q4 | -732.17 Thousand USD | 19.41% |
| 2009 Q2 | -1.76 Million USD | 41.9% |
| 2009 Q3 | -1.29 Million USD | 26.94% |
| 2009 Q4 | -1.16 Million USD | 9.49% |
| 2009 FY | -7.27 Million USD | 33.22% |
| 2009 Q1 | -3.04 Million USD | 19.7% |
| 2008 Q4 | -3.79 Million USD | -30.08% |
| 2008 Q3 | -2.91 Million USD | -18.31% |
| 2008 Q2 | -2.46 Million USD | -42.9% |
| 2008 Q1 | -1.72 Million USD | -50.89% |
| 2008 FY | -10.89 Million USD | -116.7% |
| 2007 FY | -5.02 Million USD | -73.21% |
| 2007 Q3 | -950.42 Thousand USD | 33.86% |
| 2007 Q4 | -1.14 Million USD | -20.22% |
| 2007 Q2 | -1.43 Million USD | 4.02% |
| 2007 Q1 | -1.49 Million USD | -69.14% |
| 2006 Q3 | -1.34 Million USD | -297.72% |
| 2006 Q2 | -337.47 Thousand USD | -1.22% |
| 2006 FY | -2.9 Million USD | -59.28% |
| 2006 Q1 | -333.41 Thousand USD | 74.77% |
| 2006 Q4 | -885.15 Thousand USD | 34.05% |
| 2005 Q3 | -241.85 Thousand USD | 63.4% |
| 2005 FY | -1.82 Million USD | -235.6% |
| 2005 Q4 | -1.32 Million USD | -446.48% |
| 2005 Q2 | -660.83 Thousand USD | 0.0% |
| 2005 Q1 | -660.83 Thousand USD | -389.67% |
| 2004 Q3 | -134.95 Thousand USD | 0.0% |
| 2004 Q2 | -134.95 Thousand USD | 0.0% |
| 2004 FY | -542.95 Thousand USD | -26.68% |
| 2004 Q1 | -134.95 Thousand USD | 0.0% |
| 2004 Q4 | -134.95 Thousand USD | 0.0% |
| 2003 FY | -428.61 Thousand USD | -67.46% |
| 2002 FY | -255.94 Thousand USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Akebia Therapeutics, Inc. | -46.25 Million USD | 287.677% |
| Jaguar Health, Inc. | -34.29 Million USD | 353.163% |
| Keros Therapeutics, Inc. | -169.94 Million USD | 151.084% |
| Longboard Pharmaceuticals, Inc. | -56.75 Million USD | 252.948% |
| Alnylam Pharmaceuticals, Inc. | -282.17 Million USD | 130.765% |
| Ligand Pharmaceuticals Incorporated | 11.94 Million USD | -626.947% |
| ContextLogic Inc. | -328 Million USD | 126.467% |
| MiMedx Group, Inc. | 37.11 Million USD | -133.894% |
| MEI Pharma, Inc. | 14.54 Million USD | -496.974% |
| AlloVir, Inc. | -181.33 Million USD | 147.875% |
| Novavax, Inc. | -566.51 Million USD | 115.324% |
| Aptorum Group Limited | -10.52 Million USD | 924.948% |
| Ardelyx, Inc. | -63.27 Million USD | 237.196% |
| Arrowhead Pharmaceuticals, Inc. | -205 Million USD | 142.347% |
| Psyence Biomedical Ltd. | -2.75 Million USD | 3254.706% |
| Vaxcyte, Inc. | -468.04 Million USD | 118.548% |
| Precigen, Inc. | -88.92 Million USD | 197.626% |
| Pharming Group N.V. | -4.87 Million USD | 1879.101% |
| Phathom Pharmaceuticals, Inc. | -167.31 Million USD | 151.886% |
| Pieris Pharmaceuticals, Inc. | -29.75 Million USD | 391.746% |
| Rigel Pharmaceuticals, Inc. | -20.49 Million USD | 523.659% |
| Avidity Biosciences, Inc. | -235.59 Million USD | 136.848% |
| TransCode Therapeutics, Inc. | -19.41 Million USD | 547.058% |
| Reviva Pharmaceuticals Holdings, Inc. | -24.3 Million USD | 457.154% |
| Reviva Pharmaceuticals Holdings, Inc. | -24.3 Million USD | 457.154% |
| Bicycle Therapeutics plc | -189.94 Million USD | 145.704% |
| Sangamo Therapeutics, Inc. | -274 Million USD | 131.683% |
| Sol-Gel Technologies Ltd. | -29.3 Million USD | 396.236% |
| Acelyrin, Inc. | -422.06 Million USD | 120.568% |
| SELLAS Life Sciences Group, Inc. | -37.86 Million USD | 329.243% |
| Sensei Biotherapeutics, Inc. | -37.06 Million USD | 334.222% |
| Senti Biosciences, Inc. | -92.72 Million USD | 193.621% |
| Stoke Therapeutics, Inc. | -114.77 Million USD | 175.638% |
| AbCellera Biologics Inc. | -237.2 Million USD | 136.598% |
| Alaunos Therapeutics, Inc. | -34.26 Million USD | 353.34% |
| BioXcel Therapeutics, Inc. | -171.78 Million USD | 150.536% |
| Entrada Therapeutics, Inc. | -3.16 Million USD | 2845.478% |
| Chimerix, Inc. | -93.06 Million USD | 193.281% |
| VistaGen Therapeutics, Inc. | -33.02 Million USD | 362.899% |
| Windtree Therapeutics, Inc. | -17.53 Million USD | 594.966% |
| Corbus Pharmaceuticals Holdings, Inc. | -45.07 Million USD | 292.585% |
| Sorrento Therapeutics, Inc. | -504.31 Million USD | 117.214% |
| Viracta Therapeutics, Inc. | -50.69 Million USD | 271.25% |
| Elevation Oncology, Inc. | -45.44 Million USD | 291.027% |
| Alkermes plc | 414.12 Million USD | 79.037% |
| Fortress Biotech, Inc. | -142.34 Million USD | 160.988% |
| Fortress Biotech, Inc. | -142.34 Million USD | 160.988% |
| Agenus Inc. | -159.54 Million USD | 154.411% |
| HOOKIPA Pharma Inc. | -97.69 Million USD | 188.861% |
| Dyadic International, Inc. | -8.22 Million USD | 1154.857% |
| ImmuCell Corporation | -5.74 Million USD | 1610.279% |
| Eton Pharmaceuticals, Inc. | -1.19 Million USD | 7382.886% |
| IDEAYA Biosciences, Inc. | -134.42 Million USD | 164.578% |
| Lantern Pharma Inc. | -17.87 Million USD | 585.592% |
| Immix Biopharma, Inc. | -16.14 Million USD | 637.832% |
| Incyte Corporation | 620.52 Million USD | 86.01% |
| IO Biotech, Inc. | -91.44 Million USD | 194.936% |
| Janux Therapeutics, Inc. | -72.97 Million USD | 218.955% |
| Inhibikase Therapeutics, Inc. | -20.08 Million USD | 532.12% |
| Outlook Therapeutics, Inc. | -53.12 Million USD | 263.407% |
| Syros Pharmaceuticals, Inc. | -128.98 Million USD | 167.302% |
| Kintara Therapeutics, Inc. | -8.5 Million USD | 1121.198% |
| Barinthus Biotherapeutics plc | -83.91 Million USD | 203.454% |
| Madrigal Pharmaceuticals, Inc. | -380.49 Million USD | 122.815% |
| NextCure, Inc. | -67.63 Million USD | 228.35% |
| Ocuphire Pharma, Inc. | -10.56 Million USD | 921.85% |
| Onconetix, Inc. | -36.03 Million USD | 340.913% |
| Oncternal Therapeutics, Inc. | -41.71 Million USD | 308.112% |
| Opthea Limited | -191.84 Million USD | 145.252% |
| PDS Biotechnology Corporation | -43.04 Million USD | 301.676% |
| PureTech Health plc | -146.19 Million USD | 159.379% |
| Pyxis Oncology, Inc. | -82.19 Million USD | 205.616% |
| Seer, Inc. | -103.46 Million USD | 183.906% |
| Salarius Pharmaceuticals, Inc. | -12.89 Thousand USD | 673325.312% |
| Clearside Biomedical, Inc. | -24.84 Million USD | 449.428% |
| Telomir Pharmaceuticals, Inc. Common Stock | -3.94 Million USD | 2302.206% |
| VYNE Therapeutics Inc. | -29.25 Million USD | 396.712% |
| Wave Life Sciences Ltd. | -67.99 Million USD | 227.672% |
| Xeris Biopharma Holdings, Inc. | -44.01 Million USD | 297.255% |
| C4 Therapeutics, Inc. | -139.03 Million USD | 162.441% |
| ChromaDex Corporation | -5.59 Million USD | 1650.491% |
| TRACON Pharmaceuticals, Inc. | -6.89 Million USD | 1358.51% |
| Caribou Biosciences, Inc. | -116.05 Million USD | 174.8% |
| CRISPR Therapeutics AG | -222.53 Million USD | 139.01% |
| Precision BioSciences, Inc. | -43.73 Million USD | 298.491% |
| Fate Therapeutics, Inc. | -190.51 Million USD | 145.568% |
| Innoviva, Inc. | 176.7 Million USD | 50.873% |
| Summit Therapeutics Inc. | -89.73 Million USD | 196.742% |
| Verrica Pharmaceuticals Inc. | -65.75 Million USD | 232.015% |
| Aadi Bioscience, Inc. | -71.93 Million USD | 220.685% |
| ESSA Pharma Inc. | -32.13 Million USD | 370.155% |
| GlycoMimetics, Inc. | -39.27 Million USD | 321.035% |
| GT Biopharma, Inc. | -13.57 Million USD | 739.452% |
| Inhibrx Biosciences, Inc. | -219.22 Million USD | 139.6% |
| Orchestra BioMed Holdings, Inc. | -51.5 Million USD | 268.547% |
| Alzamend Neuro, Inc. | -9.93 Million USD | 973.567% |
| Rocket Pharmaceuticals, Inc. | -259.65 Million USD | 133.433% |
| Aptose Biosciences Inc. | -52.35 Million USD | 265.811% |
| ZyVersa Therapeutics, Inc. | -14.42 Million USD | 701.993% |
| Soligenix, Inc. | -7.69 Million USD | 1227.73% |
| Century Therapeutics, Inc. | -146.54 Million USD | 159.239% |
| Kura Oncology, Inc. | -165.8 Million USD | 152.358% |
| TScan Therapeutics, Inc. | -93.45 Million USD | 192.889% |
| Intensity Therapeutics, Inc. | -8.31 Million USD | 1143.539% |
| Ocean Biomedical, Inc. | -2.48 Million USD | 3598.172% |
| CytomX Therapeutics, Inc. | -6.48 Million USD | 1438.865% |
| Autolus Therapeutics plc | -195.02 Million USD | 144.513% |
| Mineralys Therapeutics, Inc. | -84.65 Million USD | 202.546% |
| EyePoint Pharmaceuticals, Inc. | -73.66 Million USD | 217.852% |
| Eterna Therapeutics Inc. | -21.13 Million USD | 510.75% |
| Adaptive Biotechnologies Corporation | -227.03 Million USD | 138.237% |
| GRI Bio, Inc. | -11.38 Million USD | 862.378% |
| Xenetic Biosciences, Inc. | -4.51 Million USD | 2022.442% |
| Tenaya Therapeutics, Inc. | -131.19 Million USD | 166.171% |
| IGM Biosciences, Inc. | -263.46 Million USD | 132.951% |
| INmune Bio, Inc. | -29.74 Million USD | 391.893% |
| Heron Therapeutics, Inc. | -110.61 Million USD | 178.481% |
| SAB Biotherapeutics, Inc. | -38.07 Million USD | 328.001% |
| Pasithea Therapeutics Corp. | -15.97 Million USD | 643.276% |
| Entero Therapeutics, Inc. | -15.77 Million USD | 650.459% |
| Milestone Pharmaceuticals Inc. | -61.09 Million USD | 242.086% |
| X4 Pharmaceuticals, Inc. | -107.52 Million USD | 180.739% |
| Atara Biotherapeutics, Inc. | -276 Million USD | 131.453% |
| Coherus BioSciences, Inc. | -203.19 Million USD | 142.723% |
| Verastem, Inc. | -92.08 Million USD | 194.275% |
| Abeona Therapeutics Inc. | -47.13 Million USD | 284.177% |
| Pliant Therapeutics, Inc. | -184.14 Million USD | 147.143% |
| Tonix Pharmaceuticals Holding Corp. | -118.38 Million USD | 173.333% |
| Histogen Inc. | -10.64 Million USD | 915.672% |
| Aprea Therapeutics, Inc. | -15.47 Million USD | 661.092% |
| Surrozen, Inc. | -45.78 Million USD | 289.629% |
| Organovo Holdings, Inc. | -15.08 Million USD | 675.447% |
| Lixte Biotechnology Holdings, Inc. | -5.09 Million USD | 1805.461% |
| Ovid Therapeutics Inc. | -59.28 Million USD | 246.44% |
| Panbela Therapeutics, Inc. | -51.29 Million USD | 269.244% |
| CASI Pharmaceuticals, Inc. | -25.28 Million USD | 443.402% |
| Cadrenal Therapeutics, Inc. Common Stock | -7.63 Million USD | 1237.348% |
| Centessa Pharmaceuticals plc | -171.28 Million USD | 150.683% |
| Hepion Pharmaceuticals, Inc. | -48.44 Million USD | 279.186% |
| Arcturus Therapeutics Holdings Inc. | -78.2 Million USD | 211.006% |
| BioRestorative Therapies, Inc. | -15.22 Million USD | 670.352% |
| Apollomics, Inc. | -54.83 Million USD | 258.318% |
| Amarin Corporation plc | -67.58 Million USD | 228.443% |
| Mesoblast Limited | -58.79 Million USD | 247.655% |
| Turnstone Biologics Corp. | -59.03 Million USD | 247.059% |
| Kymera Therapeutics, Inc. | -165.53 Million USD | 152.445% |
| Synaptogenix, Inc. | -8.31 Million USD | 1144.185% |
| Tiziana Life Sciences Ltd | -14.58 Million USD | 695.173% |
| Aurinia Pharmaceuticals Inc. | -91.69 Million USD | 194.679% |
| BriaCell Therapeutics Corp. | -4.79 Million USD | 1911.805% |
| Monopar Therapeutics Inc. | -8.83 Million USD | 1083.011% |
| Exelixis, Inc. | 170.88 Million USD | 49.199% |
| Better Therapeutics, Inc. | -38.26 Million USD | 326.888% |
| Nurix Therapeutics, Inc. | -155.06 Million USD | 155.985% |
| Apellis Pharmaceuticals, Inc. | -517.12 Million USD | 116.788% |
| NLS Pharmaceutics AG | -11.8 Million USD | 835.255% |
| Dermata Therapeutics, Inc. | -8.04 Million USD | 1179.495% |
| Aridis Pharmaceuticals, Inc. | -29.99 Million USD | 389.441% |
| Gritstone bio, Inc. | -154.63 Million USD | 156.14% |
| Jasper Therapeutics, Inc. | -68.86 Million USD | 226.068% |
| TNF Pharmaceuticals, Inc. | -17.12 Million USD | 606.989% |
| Avid Bioservices, Inc. | -18.67 Million USD | 564.782% |
| Insmed Incorporated | -709.62 Million USD | 112.233% |
| Virpax Pharmaceuticals, Inc. | -15.68 Million USD | 653.303% |
| MediWound Ltd. | -15.29 Million USD | 667.77% |
| OmniAb, Inc. | -69.41 Million USD | 225.055% |
| Alector, Inc. | -151.74 Million USD | 157.211% |
| Seres Therapeutics, Inc. | -107.98 Million USD | 180.394% |
| Checkpoint Therapeutics, Inc. | -52.14 Million USD | 266.472% |
| Zai Lab Limited | -366.57 Million USD | 123.682% |
| Revance Therapeutics, Inc. | -316.77 Million USD | 127.405% |
| Aura Biosciences, Inc. | -84.99 Million USD | 202.143% |
| Lyell Immunopharma, Inc. | -245.49 Million USD | 135.361% |
| Immunic, Inc. | -99.22 Million USD | 187.492% |
| Tarsus Pharmaceuticals, Inc. | -143.15 Million USD | 160.641% |
| Veracyte, Inc. | -85.79 Million USD | 201.185% |
| InMed Pharmaceuticals Inc. | - USD | -Infinity% |
| FibroGen, Inc. | -281.81 Million USD | 130.805% |
| SeaStar Medical Holding Corporation | -14.21 Million USD | 710.922% |
| Adial Pharmaceuticals, Inc. | -6.88 Million USD | 1360.347% |
| Sonnet BioTherapeutics Holdings, Inc. | -18.79 Million USD | 561.947% |
| Jazz Pharmaceuticals plc | 578.58 Million USD | 84.996% |
| Cyclacel Pharmaceuticals, Inc. | -25.45 Million USD | 441.068% |
| Amylyx Pharmaceuticals, Inc. | 38.8 Million USD | -123.731% |
| TG Therapeutics, Inc. | 20.63 Million USD | -320.743% |
| Galecto, Inc. | -39.9 Million USD | 317.547% |
| Calithera Biosciences, Inc. | -42.07 Million USD | 306.332% |
| Fortrea Holdings Inc. | 63.1 Million USD | -37.578% |
| KalVista Pharmaceuticals, Inc. | -140.44 Million USD | 161.812% |
| Aptevo Therapeutics Inc. | -28.87 Million USD | 400.616% |
| XBiotech Inc. | -37.51 Million USD | 331.437% |
| Jasper Therapeutics, Inc. | -68.86 Million USD | 226.068% |
| Lyra Therapeutics, Inc. | -67.12 Million USD | 229.338% |
| Foghorn Therapeutics Inc. | -107.9 Million USD | 180.452% |
| Y-mAbs Therapeutics, Inc. | -25.67 Million USD | 438.158% |
| Theravance Biopharma, Inc. | -53.29 Million USD | 262.899% |
| Ultragenyx Pharmaceutical Inc. | -569.2 Million USD | 115.251% |
| Metagenomi, Inc. Common Stock | -78.49 Million USD | 210.6% |
| Vaxxinity, Inc. | -58.28 Million USD | 248.944% |
| BioCryst Pharmaceuticals, Inc. | -103.7 Million USD | 183.707% |
| Gain Therapeutics, Inc. | -22.25 Million USD | 490.111% |
| Cartesian Therapeutics, Inc. | -86.41 Million USD | 200.458% |
| NexImmune, Inc. | -29.19 Million USD | 397.378% |
| Creative Medical Technology Holdings, Inc. | -5.62 Million USD | 1644.661% |
| Marker Therapeutics, Inc. | -14.58 Million USD | 695.362% |
| Regeneron Pharmaceuticals, Inc. | 4.04 Billion USD | 97.855% |
| Chemomab Therapeutics Ltd. | -25.45 Million USD | 440.987% |
| Scopus BioPharma Inc. | -11.71 Million USD | 841.041% |
| RAPT Therapeutics, Inc. | -127.06 Million USD | 168.323% |
| Ainos, Inc. | -13.2 Million USD | 757.348% |
| Pluri Inc. | -22.15 Million USD | 491.786% |
| Prothena Corporation plc | -191.03 Million USD | 145.443% |
| Adaptimmune Therapeutics plc | -138.03 Million USD | 162.89% |
| Celularity Inc. | -192.28 Million USD | 145.147% |
| Rallybio Corporation | -78.93 Million USD | 209.983% |
| Cue Biopharma, Inc. | -52.14 Million USD | 266.469% |
| MeiraGTx Holdings plc | -137.06 Million USD | 163.338% |
| Omeros Corporation | -164.53 Million USD | 152.764% |
| Humacyte, Inc. | -100.04 Million USD | 186.771% |
| Immunocore Holdings plc | -59.64 Million USD | 245.538% |
| Cocrystal Pharma, Inc. | -18.55 Million USD | 567.762% |
| Cidara Therapeutics, Inc. | -24.48 Million USD | 454.581% |
| Blueprint Medicines Corporation | -486.27 Million USD | 117.852% |
| CalciMedica, Inc. | -21.87 Million USD | 496.855% |
| Cabaletta Bio, Inc. | -74.66 Million USD | 216.276% |
| Marinus Pharmaceuticals, Inc. | -131.48 Million USD | 166.024% |
| Scholar Rock Holding Corporation | -171.29 Million USD | 150.68% |
| Sana Biotechnology, Inc. | -326.9 Million USD | 126.556% |
| Pulmatrix, Inc. | -14.74 Million USD | 688.955% |
| Elicio Therapeutics, Inc. | -35.74 Million USD | 342.865% |
| Vigil Neuroscience, Inc. | -88.86 Million USD | 197.689% |
| Intellia Therapeutics, Inc. | -515.29 Million USD | 116.847% |
| Adlai Nortye Ltd. American Depositary Shares | -67.55 Million USD | 228.513% |
| Cytokinetics, Incorporated | -496.2 Million USD | 117.495% |
| Eloxx Pharmaceuticals, Inc. | -34.41 Million USD | 352.221% |
| Nutriband Inc. | -4.87 Million USD | 1881.883% |
| Protara Therapeutics, Inc. | -43.61 Million USD | 299.051% |
| Vor Biopharma Inc. | -126.03 Million USD | 168.879% |
| Roivant Sciences Ltd. | 4.24 Billion USD | 97.954% |
| Evogene Ltd. | -26.39 Million USD | 428.945% |
| ProKidney Corp. | -151.52 Million USD | 157.293% |
| Applied Therapeutics, Inc. | -64.53 Million USD | 234.519% |
| Hoth Therapeutics, Inc. | -7.69 Million USD | 1228.566% |
| BridgeBio Pharma, Inc. | -607.37 Million USD | 114.293% |
| CorMedix Inc. | -48.95 Million USD | 277.32% |
| BioLineRx Ltd. | -49.69 Million USD | 274.693% |
| Tango Therapeutics, Inc. | -114.17 Million USD | 176.035% |
| Galectin Therapeutics Inc. | -38.07 Million USD | 328.021% |
| Atai Life Sciences N.V. | -125.47 Million USD | 169.189% |
| Renovaro Biosciences Inc. | -81.63 Million USD | 206.336% |
| Aerovate Therapeutics, Inc. | -81.4 Million USD | 206.637% |
| Zentalis Pharmaceuticals, Inc. | -248.98 Million USD | 134.866% |
| Sagimet Biosciences Inc. | -30.74 Million USD | 382.407% |
| MediciNova, Inc. | -9.9 Million USD | 976.865% |
| Praxis Precision Medicines, Inc. | -126.37 Million USD | 168.695% |
| Cardio Diagnostics Holdings, Inc. | -7.24 Million USD | 1298.654% |
| GeoVax Labs, Inc. | -26.74 Million USD | 424.617% |
| Axsome Therapeutics, Inc. | -231.82 Million USD | 137.447% |
| Biomea Fusion, Inc. | -126.13 Million USD | 168.825% |
| PTC Therapeutics, Inc. | -349.4 Million USD | 124.846% |
| Mereo BioPharma Group plc | -28.41 Million USD | 405.504% |
| Cullinan Oncology, Inc. | -191.08 Million USD | 145.43% |
| Syndax Pharmaceuticals, Inc. | -229.95 Million USD | 137.752% |
| Absci Corporation | -115.51 Million USD | 175.152% |
| NRx Pharmaceuticals, Inc. | -27.58 Million USD | 414.684% |
| 4D Molecular Therapeutics, Inc. | -112.86 Million USD | 176.915% |
| Dyne Therapeutics, Inc. | -242.16 Million USD | 135.849% |
| Kiniksa Pharmaceuticals, Ltd. | -25.19 Million USD | 444.547% |
| Ventyx Biosciences, Inc. | -207.99 Million USD | 141.738% |
| Allakos Inc. | -196.05 Million USD | 144.279% |
| Imunon, Inc. | -21.03 Million USD | 512.792% |
| Fulcrum Therapeutics, Inc. | -110.66 Million USD | 178.446% |
| Corcept Therapeutics Incorporated | 107.28 Million USD | 19.081% |
| BioAtla, Inc. | -129.68 Million USD | 166.94% |
| NLS Pharmaceutics AG | -11.8 Million USD | 835.255% |
| Bio-Path Holdings, Inc. | -15.84 Million USD | 647.952% |
| Allogene Therapeutics, Inc. | -327.73 Million USD | 126.488% |
| Larimar Therapeutics, Inc. | -41.75 Million USD | 307.893% |
| XOMA Corporation | -41.84 Million USD | 307.446% |
| Kezar Life Sciences, Inc. | -105.23 Million USD | 182.492% |
| Cara Therapeutics, Inc. | -121.49 Million USD | 171.453% |
| aTyr Pharma, Inc. | -54.91 Million USD | 258.073% |
| Aligos Therapeutics, Inc. | -87.42 Million USD | 199.297% |
| Akero Therapeutics, Inc. | -172.87 Million USD | 150.218% |
| Viridian Therapeutics, Inc. | -254.45 Million USD | 134.118% |
| Eliem Therapeutics, Inc. | -21.46 Million USD | 504.416% |
| EyeGate Pharmaceuticals, Inc. | -8.21 Million USD | 1157.039% |
| Akari Therapeutics, Plc | -16.8 Million USD | 616.554% |
| Tevogen Bio Holdings Inc. | -8843.03 USD | 981799.712% |
| Halozyme Therapeutics, Inc. | 337.57 Million USD | 74.284% |
| Lexaria Bioscience Corp. | -6.53 Million USD | 1428.615% |
| UroGen Pharma Ltd. | -65.53 Million USD | 232.465% |
| Sutro Biopharma, Inc. | -89.27 Million USD | 197.238% |
| ZIVO Bioscience, Inc. | -7.26 Million USD | 1295.262% |
| Orgenesis Inc. | -53.63 Million USD | 261.854% |
| Entera Bio Ltd. | -8.89 Million USD | 1076.403% |
| GH Research PLC | -41.22 Million USD | 310.596% |
| Lisata Therapeutics, Inc. | -25.7 Million USD | 437.685% |
| Reneo Pharmaceuticals, Inc. | -83.05 Million USD | 204.526% |
| Xencor, Inc. | -138.63 Million USD | 162.617% |
| 60 Degrees Pharmaceuticals, Inc. | -5.15 Million USD | 1784.171% |
| Replimune Group, Inc. | -234.77 Million USD | 136.977% |
| Coeptis Therapeutics Holdings, Inc. | -21.49 Million USD | 503.944% |
| Vanda Pharmaceuticals Inc. | -13.95 Million USD | 722.219% |
| Lexaria Bioscience Corp. | -6.53 Million USD | 1428.615% |
| Portage Biotech Inc. | -18.25 Million USD | 575.604% |
| Cardio Diagnostics Holdings, Inc. | -7.24 Million USD | 1298.654% |
| Olema Pharmaceuticals, Inc. | -104.96 Million USD | 182.709% |
| OncoCyte Corporation | -25.13 Million USD | 445.369% |
| Qualigen Therapeutics, Inc. | -11.3 Million USD | 867.918% |
| Processa Pharmaceuticals, Inc. | -11.45 Million USD | 857.716% |
| Purple Biotech Ltd. | 22.27 Million USD | -289.798% |
| CollPlant Biotechnologies Ltd. | -7.51 Million USD | 1255.644% |
| scPharmaceuticals Inc. | -55.39 Million USD | 256.712% |
| ProMIS Neurosciences, Inc. | -18.89 Million USD | 559.379% |
| HilleVax, Inc. | -133.34 Million USD | 165.103% |
| NeuroSense Therapeutics Ltd. | -12.04 Million USD | 820.491% |
| Tharimmune, Inc. | -9.45 Million USD | 1018.138% |
| Genprex, Inc. | -31.07 Million USD | 379.358% |
| Neumora Therapeutics, Inc. Common Stock | -188.19 Million USD | 146.129% |
| Atossa Therapeutics, Inc. | -31.37 Million USD | 376.674% |
| XTL Biopharmaceuticals Ltd. | -765 Thousand USD | 11447.974% |
| Virios Therapeutics, Inc. | -5.44 Million USD | 1693.782% |
| OKYO Pharma Limited | -15.74 Thousand USD | 551296.751% |
| Savara Inc. | -60 Million USD | 244.67% |
| Curis, Inc. | -48.33 Million USD | 279.616% |
| Daré Bioscience, Inc. | -30.83 Million USD | 381.493% |
| Carmell Therapeutics Corporation | -5.21 Million USD | 1763.932% |
| Titan Pharmaceuticals, Inc. | -7.27 Million USD | 1292.964% |
| Achieve Life Sciences, Inc. | -27.25 Million USD | 418.576% |
| BeiGene, Ltd. | -1.2 Billion USD | 107.188% |
| Kiromic BioPharma, Inc. | -19.93 Million USD | 535.381% |
| Revolution Medicines, Inc. Warrant | -487.18 Million USD | 117.819% |
| Protagonist Therapeutics, Inc. | -93.65 Million USD | 192.696% |
| Erasca, Inc. | -141.52 Million USD | 161.34% |
| bluebird bio, Inc. | -244.26 Million USD | 135.541% |
| Protagenic Therapeutics, Inc. | -4.52 Million USD | 2017.661% |
| BioMarin Pharmaceutical Inc. | 194.44 Million USD | 55.353% |
| DBV Technologies S.A. | -76.43 Million USD | 213.581% |
| Protagenic Therapeutics, Inc. | -4.52 Million USD | 2017.661% |
| Moderna, Inc. | -4.23 Billion USD | 102.048% |
| Vincerx Pharma, Inc. | -42.6 Million USD | 303.741% |
| Fresh Tracks Therapeutics, Inc. | -6.36 Million USD | 1464.969% |
| Molecular Templates, Inc. | -10.46 Million USD | 929.467% |
| Acrivon Therapeutics, Inc. Common Stock | -67.23 Million USD | 229.113% |
| Travere Therapeutics, Inc. | -376.74 Million USD | 123.043% |
| Monte Rosa Therapeutics, Inc. | -143.31 Million USD | 160.576% |
| Spruce Biosciences, Inc. | -51.99 Million USD | 266.969% |
| Celldex Therapeutics, Inc. | -154.54 Million USD | 156.174% |
| Cogent Biosciences, Inc. | -208.13 Million USD | 141.71% |
| MacroGenics, Inc. | -168.24 Million USD | 151.599% |
| RenovoRx, Inc. | -11.39 Million USD | 861.776% |
| Adicet Bio, Inc. | -152.03 Million USD | 157.099% |
| Prime Medicine, Inc. | -191.29 Million USD | 145.382% |
| Aditxt, Inc. | -26.06 Million USD | 433.093% |
| Adagene Inc. | -23.71 Million USD | 465.989% |
| Estrella Immunopharma, Inc. | -7.31 Million USD | 1287.563% |
| Quantum-Si incorporated | -111.17 Million USD | 178.089% |
| Maravai LifeSciences Holdings, Inc. | -31.64 Million USD | 374.305% |
| Acurx Pharmaceuticals, Inc. | -14.57 Million USD | 695.51% |
| Voyager Therapeutics, Inc. | 122.01 Million USD | 28.851% |
| SciSparc Ltd. | -5.77 Million USD | 1603.759% |
| Vericel Corporation | -6.46 Million USD | 1443.007% |
| Revelation Biosciences, Inc. | -8.65 Million USD | 1102.834% |
| Minerva Neurosciences, Inc. | -23.11 Million USD | 475.491% |
| Generation Bio Co. | -138.56 Million USD | 162.652% |
| Astria Therapeutics, Inc. | -83.03 Million USD | 204.555% |
| Black Diamond Therapeutics, Inc. | -86.46 Million USD | 200.407% |
| Arcutis Biotherapeutics, Inc. | -241.1 Million USD | 136.006% |
| Invivyd, Inc. | -207.78 Million USD | 141.78% |
| Relay Therapeutics, Inc. | -373 Million USD | 123.274% |
| Quoin Pharmaceuticals, Ltd. | -9.37 Million USD | 1025.649% |
| Spero Therapeutics, Inc. | 21.48 Million USD | -304.134% |
| Artelo Biosciences, Inc. | -10.28 Million USD | 943.9% |
| 2seventy bio, Inc. | -216.7 Million USD | 140.06% |
| ADMA Biologics, Inc. | 21.63 Million USD | -301.313% |
| Clene Inc. | -40.54 Million USD | 314.139% |
| Capricor Therapeutics, Inc. | -24.07 Million USD | 460.547% |
| Boundless Bio, Inc. Common Stock | -54.79 Million USD | 258.428% |
| GeoVax Labs, Inc. | -26.74 Million USD | 424.617% |
| Recursion Pharmaceuticals, Inc. | -350.06 Million USD | 124.799% |
| Citius Pharmaceuticals, Inc. | -36.73 Million USD | 336.339% |
| Contineum Therapeutics, Inc. Class A Common Stock | 16.07 Million USD | -439.976% |
| Relmada Therapeutics, Inc. | -103.7 Million USD | 183.713% |
| Finch Therapeutics Group, Inc. | -34 Million USD | 355.314% |
| ALX Oncology Holdings Inc. | -170.27 Million USD | 150.983% |
| Vir Biotechnology, Inc. | -684.3 Million USD | 112.686% |
| Evaxion Biotech A/S | -22.19 Million USD | 491.098% |
| Ocular Therapeutix, Inc. | -82.38 Million USD | 205.377% |
| Verve Therapeutics, Inc. | -223.12 Million USD | 138.908% |
| Trevena, Inc. | -35.28 Million USD | 346.01% |
| Surrozen, Inc. | -45.78 Million USD | 289.629% |
| Tyra Biosciences, Inc. | -79.94 Million USD | 208.59% |
| Cingulate Inc. | -22.75 Million USD | 481.437% |
| Galmed Pharmaceuticals Ltd. | 7.49 Million USD | -1058.729% |
| Unity Biotechnology, Inc. | -44.66 Million USD | 294.354% |
| Tenax Therapeutics, Inc. | -8.23 Million USD | 1154.319% |
| Terns Pharmaceuticals, Inc. | -102.55 Million USD | 184.647% |
| ACADIA Pharmaceuticals Inc. | -73.37 Million USD | 218.306% |
| Connect Biopharma Holdings Limited | -62.07 Million USD | 239.852% |
| Clearmind Medicine Inc. | -8.74 Million USD | 1093.119% |
| Kronos Bio, Inc. | -121.83 Million USD | 171.257% |
| Bolt Biotherapeutics, Inc. | -76.19 Million USD | 213.932% |
| CERo Therapeutics Holdings, Inc. | -2.93 Million USD | 3059.851% |
| Viking Therapeutics, Inc. | -100.82 Million USD | 186.1% |
| Statera Biopharma, Inc. | -98.34 Million USD | 188.274% |
| ImmunityBio, Inc. | -362.25 Million USD | 123.965% |
| Korro Bio, Inc. | -84.53 Million USD | 202.695% |
| Kineta, Inc. | -15.72 Million USD | 652.134% |
| BioVie Inc. | -32.17 Million USD | 369.774% |
| Codexis, Inc. | -68.06 Million USD | 227.535% |
| Celularity Inc. | -192.28 Million USD | 145.147% |
| Crinetics Pharmaceuticals, Inc. | -222.6 Million USD | 138.998% |
| Celcuity Inc. | -66.23 Million USD | 231.076% |
| Virax Biolabs Group Limited | -6.49 Million USD | 1436.294% |
| Cibus, Inc. | -318.88 Million USD | 127.224% |
| Eledon Pharmaceuticals, Inc. | -43 Million USD | 301.888% |
| eFFECTOR Therapeutics, Inc. | -33.84 Million USD | 356.506% |
| IN8bio, Inc. | -30.33 Million USD | 386.159% |
| Kodiak Sciences Inc. | -277.32 Million USD | 131.304% |
| Annexon, Inc. | -143.72 Million USD | 160.402% |
| Adverum Biotechnologies, Inc. | -123.79 Million USD | 170.128% |
| Assembly Biosciences, Inc. | -64.64 Million USD | 234.288% |
| Avalo Therapeutics, Inc. | -23.44 Million USD | 470.295% |
| Ionis Pharmaceuticals, Inc. | -353.73 Million USD | 124.542% |
| Eyenovia, Inc. | -25.4 Million USD | 441.693% |
| Puma Biotechnology, Inc. | 32.64 Million USD | -165.968% |
| Conduit Pharmaceuticals Inc. | -5.56 Million USD | 1660.805% |
| Xilio Therapeutics, Inc. | -79.13 Million USD | 209.704% |
| Arcellx, Inc. | -89.88 Million USD | 196.587% |
| Cardiff Oncology, Inc. | -45.41 Million USD | 291.165% |
| Enanta Pharmaceuticals, Inc. | -137.2 Million USD | 163.271% |
| Regulus Therapeutics Inc. | -31.1 Million USD | 379.058% |
| Moolec Science SA | -6.65 Million USD | 1404.697% |
| Acumen Pharmaceuticals, Inc. | -61.13 Million USD | 241.994% |
| Geron Corporation | -193.94 Million USD | 144.761% |
| LAVA Therapeutics N.V. | -43.25 Million USD | 300.707% |
| Royalty Pharma plc | 1.49 Billion USD | 94.182% |
| Atea Pharmaceuticals, Inc. | -164.16 Million USD | 152.882% |
| Greenwich LifeSciences, Inc. | -9.32 Million USD | 1030.674% |
| TFF Pharmaceuticals, Inc. | -21.89 Million USD | 496.498% |
| Mersana Therapeutics, Inc. | -170.95 Million USD | 150.78% |
| Humacyte, Inc. | -100.04 Million USD | 186.771% |
| Structure Therapeutics Inc. | -102.77 Million USD | 184.468% |
| 89bio, Inc. | -151.2 Million USD | 157.414% |
| PMV Pharmaceuticals, Inc. | -80.13 Million USD | 208.336% |
| Avenue Therapeutics, Inc. | -14.54 Million USD | 697.056% |
| Genelux Corporation | -24.16 Million USD | 459.247% |
| Trevi Therapeutics, Inc. | -33.92 Million USD | 355.909% |
| Lexicon Pharmaceuticals, Inc. | -171.75 Million USD | 150.546% |
| Notable Labs, Ltd. | -14.65 Million USD | 692.29% |
| Liquidia Corporation | -73.38 Million USD | 218.298% |
| Mustang Bio, Inc. | -50.72 Million USD | 271.139% |
| Immunovant, Inc. | -282.7 Million USD | 130.707% |
| Quantum-Si incorporated | -111.17 Million USD | 178.089% |
| Arbutus Biopharma Corporation | -78.1 Million USD | 211.151% |
| DiaMedica Therapeutics Inc. | -21.26 Million USD | 508.2% |
| Vera Therapeutics, Inc. | -102.01 Million USD | 185.1% |
| Acasti Pharma Inc. | -11.31 Million USD | 867.433% |
| MiNK Therapeutics, Inc. | -22.92 Million USD | 478.743% |
| Pasithea Therapeutics Corp. | -15.97 Million USD | 643.276% |
| Xenon Pharmaceuticals Inc. | -214.05 Million USD | 140.556% |
| Elevai Labs, Inc. Common Stock | -3.66 Million USD | 2466.048% |
| NeuroBo Pharmaceuticals, Inc. | -15.88 Million USD | 646.469% |
| Tempest Therapeutics, Inc. | -29.15 Million USD | 397.74% |
| Soleno Therapeutics, Inc. | -41.38 Million USD | 309.772% |
| PepGen Inc. | -84.76 Million USD | 202.414% |
| Moleculin Biotech, Inc. | -29.63 Million USD | 392.977% |
| United Therapeutics Corporation | 1.18 Billion USD | 92.673% |
| Nuvectis Pharma, Inc. | -22.89 Million USD | 479.141% |
| Solid Biosciences Inc. | -104.31 Million USD | 183.221% |
| BriaCell Therapeutics Corp. | -32.8 Million USD | 364.605% |
| Immuneering Corporation | -58.41 Million USD | 248.618% |
| Lixte Biotechnology Holdings, Inc. | -5.09 Million USD | 1805.461% |
| Silo Pharma, Inc. | -3.85 Million USD | 2351.587% |
| Belite Bio, Inc | -31.66 Million USD | 374.132% |
| XOMA Corporation | -41.84 Million USD | 307.446% |
| ARS Pharmaceuticals, Inc. | -67.52 Million USD | 228.572% |
| Bionomics Limited | -17.89 Billion USD | 100.485% |
| Apogee Therapeutics, Inc. | -93 Million USD | 193.343% |
| Alpha Tau Medical Ltd. | 35.68 Million USD | -143.307% |
| uniQure N.V. | -282.87 Million USD | 130.69% |
| Cassava Sciences, Inc. | -105.95 Million USD | 181.931% |
| Estrella Immunopharma, Inc. | -7.31 Million USD | 1287.563% |
| Poseida Therapeutics, Inc. | -129.5 Million USD | 167.034% |
| Forte Biosciences, Inc. | -32.48 Million USD | 367.229% |
| Anebulo Pharmaceuticals, Inc. | -8.3 Million USD | 1144.826% |
| Enlivex Therapeutics Ltd. | -29.39 Million USD | 395.329% |
| Conduit Pharmaceuticals Inc. | -5.56 Million USD | 1660.805% |
| SeaStar Medical Holding Corporation | -14.21 Million USD | 710.922% |
| FibroBiologics, Inc. Common Stock | -8.88 Million USD | 1076.623% |
| Altimmune, Inc. | -95.92 Million USD | 190.496% |
| Amicus Therapeutics, Inc. | -73.49 Million USD | 218.121% |
| Alpha Tau Medical Ltd. | 35.68 Million USD | -143.307% |
| Compugen Ltd. | -12.99 Million USD | 768.196% |
| Peak Bio, Inc. | -1356.23 USD | 6401079.185% |
| Zevra Therapeutics, Inc. | -49.6 Million USD | 275.01% |
| Benitec Biopharma Inc. | -22.49 Million USD | 486.003% |
| Spyre Therapeutics, Inc. | -242.3 Million USD | 135.828% |
| NKGen Biotech, Inc. Common Stock | -29.74 Million USD | 391.844% |
| Zura Bio Limited | -62.63 Million USD | 238.593% |
| PolyPid Ltd. | -22.86 Million USD | 479.639% |
| Aileron Therapeutics, Inc. | -16.27 Million USD | 633.374% |
| NKGen Biotech, Inc. Warrants | -29.74 Million USD | 391.844% |
| Instil Bio, Inc. | -159.16 Million USD | 154.541% |
| argenx SE | -425.04 Million USD | 120.424% |
| Immunome, Inc. | -109.53 Million USD | 179.259% |
| Compass Therapeutics, Inc. | -50.36 Million USD | 272.373% |
| Verona Pharma plc | -67.83 Million USD | 227.983% |
| enGene Holdings Inc. Warrants | -26.06 Million USD | 433.124% |
| Shattuck Labs, Inc. | -91.95 Million USD | 194.405% |
| CervoMed Inc. | -7.81 Million USD | 1211.137% |
| LENZ Therapeutics, Inc. | -73.11 Million USD | 218.742% |
| Plus Therapeutics, Inc. | -13.32 Million USD | 751.693% |
| Dianthus Therapeutics, Inc. | -48.17 Million USD | 280.205% |
| Moolec Science SA | -6.65 Million USD | 1404.697% |
| Enveric Biosciences, Inc. | -16.44 Million USD | 627.783% |
| Inovio Pharmaceuticals, Inc. | -135.22 Million USD | 164.197% |
| AnaptysBio, Inc. | -164.41 Million USD | 152.802% |
| Design Therapeutics, Inc. | -78.19 Million USD | 211.027% |
| Leap Therapeutics, Inc. | -87.04 Million USD | 199.737% |
| NeurAxis, Inc. | -6.66 Million USD | 1402.604% |
| Seelos Therapeutics, Inc. | -40.49 Million USD | 314.356% |
| Lumos Pharma, Inc. | -36.61 Million USD | 337.101% |
| Achilles Therapeutics plc | -75.25 Million USD | 215.357% |
| enGene Holdings Inc. Common Stock | -26.06 Million USD | 433.124% |
| 180 Life Sciences Corp. | -13.47 Million USD | 744.125% |
| Opiant Pharmaceuticals, Inc. | 5.15 Million USD | -1583.607% |
| CERo Therapeutics Holdings, Inc. | -2.93 Million USD | 3059.851% |
| Nutriband Inc. | -4.87 Million USD | 1881.883% |
| ORIC Pharmaceuticals, Inc. | -110.78 Million USD | 178.364% |
| CG Oncology, Inc. Common stock | -55.44 Million USD | 256.562% |
| Fractyl Health, Inc. Common Stock | -50.83 Million USD | 270.769% |
| Rani Therapeutics Holdings, Inc. | -66.09 Million USD | 231.336% |
| MoonLake Immunotherapeutics | -54.12 Million USD | 260.397% |
| Palisade Bio, Inc. | -13.07 Million USD | 764.208% |
| Tourmaline Bio, Inc. | -45.4 Million USD | 291.178% |
| Beam Therapeutics Inc. | -176.48 Million USD | 149.189% |
| Neurogene Inc. | -55.58 Million USD | 256.184% |
| Mirum Pharmaceuticals, Inc. | -109.15 Million USD | 179.532% |
| AEON Biopharma, Inc. | -48.42 Million USD | 279.256% |
| CARGO Therapeutics, Inc. Common Stock | -96.71 Million USD | 189.765% |
| Sesen Bio, Inc. | -25.9 Million USD | 435.065% |
| Enliven Therapeutics, Inc. | -83.52 Million USD | 203.93% |
| Kiora Pharmaceuticals, Inc. | -12.58 Million USD | 789.701% |
| Iovance Biotherapeutics, Inc. | -460.55 Million USD | 118.849% |
| Taysha Gene Therapies, Inc. | -72.43 Million USD | 219.842% |
| Athira Pharma, Inc. | -125.46 Million USD | 169.192% |
| Vaccinex, Inc. | -22.88 Million USD | 479.34% |
| HCW Biologics Inc. | -25.71 Million USD | 437.564% |
| XOMA Corporation | -41.84 Million USD | 307.446% |
| Nektar Therapeutics | -137.42 Million USD | 163.17% |
| Arvinas, Inc. | -401.5 Million USD | 121.622% |
| Tevogen Bio Holdings Inc. | -8843.03 USD | 981799.712% |
| Merus N.V. | -156.54 Million USD | 155.454% |
| Omega Therapeutics, Inc. | -100.26 Million USD | 186.586% |
| Quince Therapeutics, Inc. | -34.62 Million USD | 350.757% |
| Rezolute, Inc. | -70.42 Million USD | 223.272% |
| Clene Inc. | -40.54 Million USD | 314.139% |
| Indaptus Therapeutics, Inc. | -16.37 Million USD | 630.037% |
| BeyondSpring Inc. | -23.11 Million USD | 475.582% |
| Synlogic, Inc. | -55.16 Million USD | 257.379% |
| Allarity Therapeutics, Inc. | -17.92 Million USD | 584.199% |
| Phio Pharmaceuticals Corp. | -10.82 Million USD | 902.033% |
| Peak Bio, Inc. | -1356.23 USD | 6401079.185% |
| Werewolf Therapeutics, Inc. | -40.5 Million USD | 314.335% |
| Krystal Biotech, Inc. | -109.72 Million USD | 179.116% |
| Karyopharm Therapeutics Inc. | -129.53 Million USD | 167.016% |
| SpringWorks Therapeutics, Inc. | -343.01 Million USD | 125.309% |
| Lipella Pharmaceuticals Inc. | -4.74 Million USD | 1929.18% |
| MannKind Corporation | 8.67 Million USD | -900.369% |
| Ikena Oncology, Inc. | -75.41 Million USD | 215.109% |
| Cyclerion Therapeutics, Inc. | -9.64 Million USD | 999.886% |
| Gyre Therapeutics, Inc. | -67.23 Million USD | 229.127% |
| Gossamer Bio, Inc. | -183.75 Million USD | 147.242% |
| CohBar, Inc. | -12.38 Million USD | 800.758% |
| Cognition Therapeutics, Inc. | -50.72 Million USD | 271.146% |
| NRx Pharmaceuticals, Inc. | -27.58 Million USD | 414.684% |
| Legend Biotech Corporation | -439.48 Million USD | 119.753% |
| Mural Oncology plc | -194.63 Million USD | 144.602% |
| Biora Therapeutics, Inc. | -67.14 Million USD | 229.294% |
| PaxMedica, Inc. Common Stock | -16.14 Million USD | 637.693% |
| Disc Medicine, Inc. | -91.12 Million USD | 195.267% |
| Champions Oncology, Inc. | -7.35 Million USD | 1280.152% |
| REGENXBIO Inc. | -268.12 Million USD | 132.377% |
| Ensysce Biosciences, Inc. | -10.71 Million USD | 909.95% |
| Anavex Life Sciences Corp. | -55.75 Million USD | 255.7% |
| Cellectar Biosciences, Inc. | -38.96 Million USD | 322.82% |
| Edgewise Therapeutics, Inc. | -114.35 Million USD | 175.913% |
| Vaxart, Inc. | -83.34 Million USD | 204.157% |
| PharmaCyte Biotech, Inc. | -8.52 Million USD | 1118.919% |
| Aldeyra Therapeutics, Inc. | -42.79 Million USD | 302.86% |
| Cellectis S.A. | -106.62 Million USD | 181.417% |
| Longeveron Inc. | -21.02 Million USD | 512.82% |
| Repare Therapeutics Inc. | -116.22 Million USD | 174.694% |
| Sarepta Therapeutics, Inc. | -267.82 Million USD | 132.414% |
| Inozyme Pharma, Inc. | -75.64 Million USD | 214.762% |
| Revolution Medicines, Inc. | -487.18 Million USD | 117.819% |
| Nymox Pharmaceutical Corporation | -6.65 Million USD | 1405.051% |
| Third Harmonic Bio, Inc. | -43.95 Million USD | 297.506% |
| ArriVent BioPharma, Inc. Common Stock | -74.59 Million USD | 216.386% |
| AN2 Therapeutics, Inc. | -69.63 Million USD | 224.667% |
| Anixa Biosciences, Inc. | -11.01 Million USD | 888.412% |
| Vertex Pharmaceuticals Incorporated | 4.3 Billion USD | 97.985% |
| Denali Therapeutics Inc. | -196.69 Million USD | 144.134% |
| Revelation Biosciences, Inc. | -8.65 Million USD | 1102.834% |
| Veru Inc. | -93.78 Million USD | 192.568% |
| Corvus Pharmaceuticals, Inc. | -23.32 Million USD | 472.121% |
| Cingulate Inc. | -22.75 Million USD | 481.437% |
| Passage Bio, Inc. | -108.38 Million USD | 180.093% |
| Context Therapeutics Inc. | -25.07 Million USD | 446.242% |
| Exicure, Inc. | -14.99 Million USD | 678.901% |
| Day One Biopharmaceuticals, Inc. | -206.06 Million USD | 142.129% |
| Oramed Pharmaceuticals Inc. | -40.59 Million USD | 313.833% |
| Scinai Immunotherapeutics Ltd. | -9.71 Million USD | 993.409% |
| Rhythm Pharmaceuticals, Inc. | -184.35 Million USD | 147.089% |
| Nuvalent, Inc. | -149.49 Million USD | 158.071% |
| ABVC BioPharma, Inc. | -8.21 Million USD | 1156.556% |
| Carisma Therapeutics, Inc. | -88.73 Million USD | 197.837% |
| Unicycive Therapeutics, Inc. | -20.77 Million USD | 517.888% |
| OmniAb, Inc. | -69.41 Million USD | 225.055% |
| Anew Medical, Inc. | -1.3 Million USD | 6773.534% |
| Fennec Pharmaceuticals Inc. | -12.77 Million USD | 779.759% |
| Lipocine Inc. | -17.93 Million USD | 584.146% |
| Lexeo Therapeutics, Inc. Common Stock | -68.51 Million USD | 226.709% |
| Nautilus Biotechnology, Inc. | -76.15 Million USD | 213.998% |
| SAB Biotherapeutics, Inc. | -38.07 Million USD | 328.001% |
| G1 Therapeutics, Inc. | -39.52 Million USD | 319.627% |
| Bellerophon Therapeutics, Inc. | -22.38 Million USD | 487.831% |
| Sage Therapeutics, Inc. | -579.84 Million USD | 114.971% |
| Ocugen, Inc. | -65.53 Million USD | 232.475% |
| Mind Medicine (MindMed) Inc. | -93.86 Million USD | 192.485% |
| Q32 Bio Inc. | -92.1 Million USD | 194.256% |
| Brainstorm Cell Therapeutics Inc. | -21.43 Million USD | 504.926% |
| Alumis Inc. Common Stock | -158.17 Million USD | 154.884% |
| Equillium, Inc. | -14.52 Million USD | 697.796% |
| Kyverna Therapeutics, Inc. | -62.4 Million USD | 239.108% |
| Coya Therapeutics, Inc. | -7.9 Million USD | 1198.42% |
| CNS Pharmaceuticals, Inc. | -18.86 Million USD | 560.172% |
| Galera Therapeutics, Inc. | -46.95 Million USD | 284.899% |
| Evelo Biosciences, Inc. | -108.46 Million USD | 180.036% |
| Comera Life Sciences Holdings, Inc. | -11.97 Million USD | 825.246% |
| Dominari Holdings Inc. | -21.79 Million USD | 498.293% |
| Edesa Biotech, Inc. | -9.22 Million USD | 1041.28% |
| vTv Therapeutics Inc. | -25.5 Million USD | 440.413% |
| Bio-Techne Corporation | 206.68 Million USD | 57.998% |
| Agios Pharmaceuticals, Inc. | -391.48 Million USD | 122.175% |
| Harmony Biosciences Holdings, Inc. | 192.03 Million USD | 54.792% |
| Prelude Therapeutics Incorporated | -132.27 Million USD | 165.629% |
| Candel Therapeutics, Inc. | -38.39 Million USD | 326.126% |
| iTeos Therapeutics, Inc. | -151.1 Million USD | 157.453% |
| Nkarta, Inc. | -131.65 Million USD | 165.942% |
| BioCardia, Inc. | -11.64 Million USD | 845.551% |
| Iterum Therapeutics plc | -47.46 Million USD | 282.885% |